These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4194998)

  • 1. Recurrence of hyperthyroidism shortly after return of normal suppressibility by triiodothyronine.
    Wils JA; Kloppenborg PW
    Br Med J; 1970 Aug; 3(5718):327. PubMed ID: 4194998
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppressibility of thyroid function during treatment with antithyroid drugs in Grave's disease.
    Wils JA; Kloppenborg PW
    J Clin Endocrinol Metab; 1970 Mar; 30(3):406-7. PubMed ID: 4189571
    [No Abstract]   [Full Text] [Related]  

  • 3. [The inhibition test of thyroid function with triiodothyronine in hyperthyroid patients under medical therapy: comparison of the values obtained from measures of "early" uptake and in the organic phase].
    Valentini F; Reschini E; Lodeserto A; Vivarelli S; Miedico D
    Folia Endocrinol; 1968 Aug; 21(4):396-403. PubMed ID: 4185869
    [No Abstract]   [Full Text] [Related]  

  • 4. [Follow up studies of the antithyroid drug therapy for hyperthyroidism with special emphasis on the clinical usefulness of TRH and T3-suppression tests during treatment (author's transl)].
    Tamai H
    Fukuoka Igaku Zasshi; 1978 Nov; 69(11):486-94. PubMed ID: 83955
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hyperthyroidism].
    Bürgi U; Maurer P
    Schweiz Rundsch Med Prax; 1994 Jan; 83(3):61-4. PubMed ID: 7507596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emotion and non-specific infection as possible aetiological factors in Graves' disease. Their relation to thyroid suppressibility.
    Alexander WD; Harden RM; Shimmins J
    Lancet; 1968 Jul; 2(7561):196-7. PubMed ID: 4173409
    [No Abstract]   [Full Text] [Related]  

  • 7. The response in toxic diffuse goitre to a short course of antithyroid therapy.
    Clark F; Hall R; Anderson J; Farmer FT
    Clin Sci; 1970 Jul; 39(1):2P. PubMed ID: 4194428
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical practice. Graves' disease.
    Brent GA
    N Engl J Med; 2008 Jun; 358(24):2594-605. PubMed ID: 18550875
    [No Abstract]   [Full Text] [Related]  

  • 9. Thyroidal suppressibility after stopping long-term treatment of thyrotoxicosis with anti-thyroid drugs.
    Alexander WD; Harden RM; McLarty D; Shimmins J
    Metabolism; 1969 Jan; 18(1):58-62. PubMed ID: 4179400
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.
    Lamberg BA; Aro A; Saarinen P; Tötterman T; Mäkinen T
    J Endocrinol Invest; 1978 Jan; 1(1):9-16. PubMed ID: 90688
    [No Abstract]   [Full Text] [Related]  

  • 11. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responsiveness to thyrotropin releasing hormone and thyroid suppressibility in Graves' disease patients remaining in remission after antithyroid drug therapy.
    Rajatanavin R; Mahatumarat P; Poochanugool L; Kumpolpunth S; Himathongkam T
    J Med Assoc Thai; 1981 Jan; 64(1):11-8. PubMed ID: 6163837
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?
    Schleusener H; Finke R; Kotulla P; Wenzel KW; Meinhold H; Roedler HD
    J Endocrinol Invest; 1978 Apr; 1(2):155-61. PubMed ID: 90689
    [No Abstract]   [Full Text] [Related]  

  • 15. [Dynamics of PBI behavior in blood serum of patients with Graves-Basedow disease and toxic nodular goiter during treatment with methimetazole].
    Jaruga-Dolińska E; Zembrzuska Z; Korman E
    Endokrynol Pol; 1971; 22(6):535-43. PubMed ID: 4110630
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of thyrotoxicosis based on thyroidal suppressiblity.
    Alexander WD; Harden RM; Shimmins J; McLarty D; McGill P
    Lancet; 1967 Sep; 2(7518):681-4. PubMed ID: 4167095
    [No Abstract]   [Full Text] [Related]  

  • 17. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves' disease.
    Tagami T; Hagiwara H; Kimura T; Usui T; Shimatsu A; Naruse M
    Thyroid; 2007 Aug; 17(8):767-72. PubMed ID: 17651013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of treatment of Graves' disease by antithyroid drugs. Report of 90 cases (author's transl)].
    Duprey J; Colliard M
    Ann Endocrinol (Paris); 1981; 42(3):233-49. PubMed ID: 6172076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.